HOME >> BIOLOGY >> NEWS
Penn leads $4 million grant to study gene-environment interactions in lung cancer

PHILADELPHIA - The University of Pennsylvania School of Medicine, in association with Pennsylvania State University Medical College and Lincoln University, has received $4.2 million to study gene-environment interactions that increase the risk of lung cancer in African American and Caucasian smokers and non-smokers. The funds were awarded from Pennsylvanias share of the national tobacco settlement for 2006-2007.

The award, which was announced by Governor Rendell last month, will fund the establishment of a Center for Gene-Environment Interactions in Lung Cancer directed by Steve Whitehead, PhD, Professor of Pharmacology. The study will be conducted under the Gene-Environment Initiative of Penns Center of Excellence in Environmental Toxicology (CEET), directed by Trevor M. Penning, PhD.

Lung cancer is the leading cause of cancer deaths in the adult U.S. population. This year alone 174,500 new cases of lung cancer will be diagnosed and almost as many deaths will result, notes Penning. Eighty-five to ninety percent of all lung cancer is seen in individuals who smoke cigarettes, yet only ten-percent of those who smoke will succumb to the disease. These statistics suggest that a significant gene-environment interaction exists.

Cigarette smoke contains two major classes of cancer-causing chemicals: those derived from nicotine and those derived from polycyclic aromatic hydrocarbons (PAHs). PAHs are also produced by burning fossil fuels and are ubiquitous environmental pollutants. PAHs are present in soot that is found at relatively high concentrations in the air we breathe in urban environments, explains Penning. Exposure to environmental PAHs may also account for lung-cancer incidence in people who have never smoked.

The researchers aim to enroll and compare 600 lung-cancer patients from Philadelphia, which has high concentrations of air pollutants, and 600 patients from Hershey, Pa., which has comparatively unpolluted air. In
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
27-Apr-2007


Page: 1 2 3

Related biology news :

1. Acute sleep deprivation leads to changes in nighttime urine production for men and women
2. Biodesign Institute leads innovative project to prevent cancer
3. Screening approach leads to discovery of gene linked to breast cancer
4. Alcohol use during pregnancy leads to greater risk of extreme preterm delivery
5. Study of unexplained respiratory infections leads researchers to new virus
6. FSU leads botanical research into 21st century: Deep South Plant Specimen Imaging Project
7. Old dinosaur research leads to new honor
8. Long-term marijuana smoking leads to respiratory complaints
9. Trusting your instincts leads you to the right answer
10. Childrens Hospital researcher leads multipronged attack on infant leukemia
11. How brain injury leads to seizures, memory problems

Post Your Comments:
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... the world's largest provider of surgical instruments to the Spine Industry. The acquisition ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: